NEW YORK (GenomeWeb) – Curetis today reported a 41 percent year-over-year increase in its first quarter revenues, thanks largely to surging sales of its diagnostic test cartridges and instruments in Europe, the Middle East, and Asia (EMEA).

For the three-month period ended March 31, Curetis' revenues climbed to €490,000 ($577,490) from €347,000 a year earlier. Contributing to the growth was a 518 percent bounce in sales of the firm's Unyvero molecular diagnostic instrument and related cartridges in EMEA direct selling markets.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.